Skip to main
LBRX

LBRX Stock Forecast & Price Target

LBRX Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LB Pharmaceuticals is well positioned for future growth with its novel LB-102 drug in late-stage clinical development for schizophrenia and bipolar depression. Its promising results, favorable safety profile, and potential market exclusivity make it a strong contender in the growing neuropsychiatry market. With a strong financial position and potential for partnership, the company is poised for success in bringing this much-needed drug to market.

Bears say

LB Pharmaceuticals is currently focused on developing LB-102, a drug for the treatment of neuropsychiatric disorders, particularly schizophrenia and bipolar depression. However, with a discounted cash flow-based valuation method and a relatively low probability of approval (POA) for LB-102, the company's prospects may be risky. In addition, the company has not yet been profitable and may not begin generating revenue until 2029. Without projected revenue in 2026 and 2027, the potential for long-term equity dilution and the challenging reimbursement landscape in the United States, the stock may have limited potential for growth.

LBRX has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LB Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LB Pharmaceuticals Inc (LBRX) Forecast

Analysts have given LBRX a Buy based on their latest research and market trends.

According to 7 analysts, LBRX has a Buy consensus rating as of Sep 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LB Pharmaceuticals Inc (LBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.